Vimarsana
Biggest News Aggregation in the World

Page 3 - Efficacy Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Efficacy Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Efficacy Response Today - Breaking & Trending Today

Testosterone Tx Improves Anemia in Male Hypogonadism - Vimarsana News

Testosterone Tx Improves Anemia in Male Hypogonadism

A large RCT found testosterone replacement therapy more effective than placebo in middle-aged and older men with hypogonadism.

Testosterone Replacement Therapy Can Correct, Prevent Anemia - Vimarsana News

Testosterone Replacement Therapy Can Correct, Prevent Anemia

Nearly 15% of older men with hypogonadism experience anemia. TRAVERSE is the first trial to report the effects of testosterone replacement therapy (TRT) on anemia incidence in hypogonal men.

Testosterone Therapy Does Not Up Major Cardiovascular Events in High-Risk Men - Vimarsana News

Testosterone Therapy Does Not Up Major Cardiovascular Events in High-Risk Men

Trial findings help characterize the cardiovascular risk profile of testosterone-replacement therapy in at-risk men with hypogonadism.

Source: empr.com
Testosterone Therapy Does Not Up Major Cardiovascular Events in High-Risk Men - Vimarsana News

Testosterone Therapy Does Not Up Major Cardiovascular Events in High-Risk Men

Trial findings help characterize the cardiovascular risk profile of testosterone-replacement therapy in at-risk men with hypogonadism.

TRAVERSE Trial: No Increased Cardiovascular Risk with Testosterone Replacement Therapy - Vimarsana News

TRAVERSE Trial: No Increased Cardiovascular Risk with Testosterone Replacement Therapy

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.